SAN DIEGO, CA--(Marketwire - Aug 24, 2012) - Lpath, Inc. (OTCQB: LPTN), the industry leader in lipidomics-based therapeutics, has been invited to present at the 2012 Gateway Conference being held on September 6 at the W San Francisco Hotel.
Lpath management is scheduled to present at 11:30 a.m. Pacific time, with one-on-one meetings held throughout the day. Management will discuss its pathway to regulatory approval and commercialization of its novel lipidomics-based therapeutics, including the imminent resumption of Nexus, a Phase 2 trial where, in partnership with Pfizer, Lpath's anti-S1P antibody iSONEP is being studied in wet-AMD patients.
The presentation will be webcast live at www.gateway-conference.com, under the 'Presenting Companies' tab. A webcast replay will be available for 90 days.
To schedule a one-on-one meeting, visit www.gateway-conference.com and click on the Register/Login tab. You may also email your request to firstname.lastname@example.org, or call Ron Both at (949) 574-3860.
About the Gateway Conference
Gateway Conference is designed to provide a unique gateway between influential members of the investment community and a select group of compelling publicly-traded companies. Portfolio managers, research analysts and brokers from buy-side and sell-side institutions will have the opportunity to learn about more than 50 emerging growth companies across a broad range of industries, from technology, business services and digital media, to clean-tech, consumer/retail, life sciences and natural resources. For more information, go to www.gateway-conference.com.
The invitation-only conference is hosted by Liolios Group, one of the nation's top investor relations agencies, and sponsored by leading firms that service the financial community. For more information about Liolios Group, visit www.liolios.com.
San Diego-based Lpath, Inc. (OTCQB: LPTN), a therapeutic antibody company, is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, two of which -- iSONEP™ for wet AMD and ASONEP™ for cancer -- have completed Phase 1 clinical trials. The third candidate is an anti-LPA antibody that holds promise in neuropathic pain and neurotrauma. Lpath entered into an agreement with Pfizer (NYSE: PFE) in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP. For more information, visit www.Lpath.com.